Trial Profile
A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Naxitamab (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 07 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 07 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.
- 31 May 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.